Algemeen Ziekenhuis Klina | Cardiology Department
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Safety Run-in Cohort 1 and Phase 2 Cohorts 1
Safety Run-in Cohort 2 and Phase 2 Cohort 3
Key Exclusion Criteria:
Safety Run-in Cohort 1, Pre-expansion Safety Run-in Cohort for Magrolimab + Pembrolizumab (if Applicable), and Phase 2 Cohorts 1 and 2
Prior treatment with any of the following:
Safety Run-in Cohort 2 and Phase 2 Cohort 3
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
230 participants in 8 patient groups
Loading...
Central trial contact
Gilead Clinical Study Information Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal